本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 湖北均瑶大健康饮品股份有限公司（下称"均瑶健康"，股票代码：605388.SH）于近日发布2025年年度 业绩预告。公告显示，公司预计2025年年度实现归属于上市公司股东的净利润为-2.16亿元到-1.44亿 元。 （来源：公司公告） 据公告，与上年同期相比，均瑶健康归属于上市公司股东的净利润将减少1.15亿元到1.87亿元，同比减 少395.14%到642.71%。上年同期该指标为-2911.64万元。 同时，公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-2.33亿元到-1.55 亿元，与上年同期相比将减少9704.89万元到1.75亿元，同比减少167.33%到301.00%。上年同期该指标 为-5799.79万元。 公告披露，业绩变动主要受市场环境影响，公司表示报告期内消费环境持续承压，含乳饮料市场份额有 所缩减，下游客户需求不振，公司传统常温乳酸菌业务收入水平较去年同期减少。 目前，这家公司正面临着传统核心产品"味动力"增长失速与新业务投入产出不成正比的双重问题。 "味动力"是均瑶健康主打的一款乳酸菌产品 ...

Core Viewpoint - Junyao Health, known as the "first stock of ambient lactic acid bacteria" in A-shares, is facing significant financial challenges, with a projected net loss of between -216 million to -144 million yuan for 2025, marking a year-on-year decrease of 395.14% to 642.71% [2][15][25] Financial Performance - The company expects a substantial decline in net profit for 2025, with a projected loss of -233 million to -155 million yuan, representing a year-on-year decrease of 167.33% to 301.00% [2][15] - Since its listing in 2020, Junyao Health has experienced revenue growth, but net profit has consistently declined, showcasing a typical "increased revenue without increased profit" pattern, culminating in significant losses in 2025 [2][15][25] - Junyao Health's net profit has decreased for five consecutive years, with a reported revenue of 1.458 billion yuan in 2024, down 10.77% year-on-year, and a net profit of -29.12 million yuan, a decline of 150.57% [4][17] Factors Contributing to Losses - The anticipated losses for 2025 are attributed to several factors, including a challenging consumer environment leading to reduced market share in the dairy beverage sector, increased sales and marketing expenses, and higher research and development costs [4][17] - Significant impairment provisions for inventory and receivables, totaling an impact of 80 million to 140 million yuan, are identified as core drivers of the profit decline [4][17] - The company has previously reported substantial impairment losses, including 36.43 million yuan for goodwill and 12.76 million yuan for inventory write-downs in 2024, which have severely affected profitability [5][18] Market and Product Strategy - Junyao Health has attempted a "second entrepreneurship" strategy since 2021, focusing on upstream integration, new product launches, and diversification to mitigate reliance on single products [21] - Despite launching numerous new products since 2023, including those targeting specific consumer needs, the market response has been lukewarm, failing to generate significant sales volume or new growth points [10][23] - The company's marketing expenditures have surged, with sales expenses increasing by 30.27% to 245 million yuan in 2024 and a further 70.65% increase in the first half of 2025, which has further eroded profits [11][24] Stock Performance - Junyao Health's stock price has been on a downward trend since 2022, reaching a historical low of 4.18 yuan per share in 2024, and as of January 30, 2026, the stock price was 6.94 yuan, significantly lower than its initial offering price of 13.43 yuan [6][20] Future Outlook - Despite the current challenges, the dairy beverage industry still presents growth opportunities, with trends towards functionality, premiumization, and diversification [25][26] - Junyao Health possesses advantages in strain research and development, brand accumulation, and channel distribution, which could support a turnaround if strategic adjustments are made [25] - The company needs to focus on core business strengths, optimize product structure, and enhance cost control to gradually reverse the declining performance trend [25][26]

Core Viewpoint - The company, Hubei Junyao Health Beverage Co., Ltd., is experiencing significant declines in its financial performance for the first half of 2025, with net profit expected to drop by 74.23% to 82.82% compared to the same period last year, primarily due to a challenging consumption environment and increased costs associated with business restructuring and R&D efforts [1][3][14]. Financial Performance Summary - The projected net profit for the first half of 2025 is estimated to be between 5.97 million and 8.96 million yuan, a decrease of 2.58 million to 2.88 million yuan from the previous year [1]. - The company's net profit after deducting non-recurring items is expected to fall by 93.19% to 95.46%, with a reduction of 2.78 million to 2.85 million yuan [1]. - In 2024, the company reported a total revenue of 1.458 billion yuan, a year-on-year decrease of 10.77%, and a net profit of -29.12 million yuan, marking its first annual loss since its listing in 2020 [8][9]. Reasons for Performance Decline - The decline in traditional room-temperature yogurt business due to a sluggish consumption environment and shrinking market share has directly impacted profits [3]. - Expansion into e-commerce and new retail channels has led to increased upfront sales and marketing expenses, further squeezing profit margins [3]. - Increased R&D investments have expanded the functional strain resource library from over 6,000 to over 40,000 strains, which, while beneficial for long-term growth, has raised short-term costs [3]. Regulatory Issues - The company faced regulatory scrutiny for failing to timely disclose its expected losses for 2024, resulting in warnings from the Hubei Securities Regulatory Bureau and disciplinary actions from the Shanghai Stock Exchange [5][7]. - Key executives were held responsible for the disclosure violations, emphasizing the need for improved compliance with information disclosure obligations [7]. Business Challenges - The core probiotic beverage segment saw a revenue decline of 2.71% in 2024, with inventory levels significantly increasing, indicating supply-demand imbalances [11]. - The company’s attempts to diversify into the bottled water market and supply chain management have not yielded expected results, with significant challenges in both areas [12][11]. Positive Developments - Despite overall challenges, the company reported a 139.19% increase in revenue from probiotic foods in the first quarter of 2025, driven by strong online sales growth [13]. - The international business segment also showed promising growth, with a 24.54% increase in revenue in 2024 and a further 77.43% increase in the first quarter of 2025 [13]. Conclusion - The company is undergoing a critical transformation phase, facing multiple challenges including declining traditional business performance, regulatory issues, and increased costs from strategic investments. However, there are signs of potential recovery in online and international markets, indicating a complex but evolving business landscape [14].

Core Viewpoint - Hubei Junyao Health Beverage Co., Ltd. responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about trading financial assets, other receivables, and subsidiary equity acquisitions [1] Group 1: Trading Financial Assets - Junyao Health reported a year-end balance of trading financial assets of 155 million yuan, an increase of 84.27% year-on-year, with trust financial products accounting for 134 million yuan [2] - The trust plan "Aijian Win-Win - Shanghai Huade Accounts Receivable Debt Collection Fund Trust Plan" was established on July 28, 2023, with a term of 36 months and a maximum scale of 370 million yuan, raising 305.2 million yuan, with Junyao Health subscribing 130 million yuan at an annualized benchmark interest rate of 7.1% [2] Group 2: Other Receivables - The balance of other receivables at the end of the reporting period was 124 million yuan, with a bad debt provision of 16.16 million yuan [4] - The significant other receivables primarily stemmed from a partnership with Shengjiao Winery, which ended in December 2022, where Junyao Health is owed unconsumed prepayments [4] Group 3: Supply Chain Business - Junyao Health's supply chain business recognized sales revenue of 582 million yuan in 2024, down from 809 million yuan in the previous year [6] - The company engaged in transactions with Yihe (Shanghai) Supply Chain Management Co., Ltd., with procurement and sales amounts showing a downward trend [7] Group 4: Subsidiary Equity Acquisitions - During the reporting period, Junyao Health's subsidiary Meiri Boshi acquired three e-commerce companies, with the first two being established only 20 days prior to the acquisition [8] - The acquisitions aimed to quickly enter the online market and utilize existing e-commerce store qualifications to bypass platform review cycles, with the acquisitions being zero-cost [8]

Core Viewpoint - Junyao Health's stock has experienced a significant increase, with a cumulative rise of 33.23% over three consecutive trading days, despite the company's announcement that there have been no major changes in its main business operations [1][2]. Financial Performance - In Q1 of this year, Junyao Health reported a revenue increase of 1.41% year-on-year, but net profit decreased by 58.29% [1][3]. - For the year 2024, the company’s revenue was 1.458 billion yuan, a decline of 10.8%, and it recorded a net loss of 29.12 million yuan, a decrease of 150.6% year-on-year [3]. - The traditional beverage business has shown weak performance, contributing to the overall revenue decline, while the probiotic business has demonstrated strong growth, accounting for 54.3% of total revenue in 2024 [3]. E-commerce Growth - Junyao Health has seen explosive growth in its e-commerce channels, with sales increasing by 177.49% in 2024 and a staggering 1173.33% in Q1 of 2025 [4]. - The company has optimized its product layout and focused on market demand, enhancing its competitiveness in online channels [4]. International Market Performance - In 2024, Junyao Health achieved approximately 84.6 million yuan in revenue from overseas markets, reflecting a year-on-year growth of 24.54%, with Q1 of 2025 showing a significant increase of 77.43% [4]. Future Growth Drivers - The company aims to strengthen its beverage core business, expand probiotic health products, and increase raw material exports, leveraging its proprietary strain resources and production capacity [5][6].

Group 1: Lactobacillus Business Trends - The company positions its lactobacillus business within the broader health beverage framework, moving beyond a single category focus [1] - The lactobacillus beverage segment has seen a decline due to insufficient innovation compared to the overall beverage industry [1] - Sales performance for the lactobacillus business is expected to show slight growth in 2024, driven by increased orders during the Spring Festival, but will be impacted by the absence of this effect in Q1 2025 [1] Group 2: International Expansion and Probiotics Business - The company's overseas operations have shown strong performance, with a 77% year-on-year increase in overseas revenue in Q1 2025 [2] - Significant growth in orders from major U.S. clients reflects the company's long-term strategy of nurturing relationships through technical communication [2] - The company avoids competing in the low-end domestic market, focusing instead on establishing long-term technical collaborations with professional clients [2] Group 3: E-commerce and Brand Performance - The "Daily Doctor" brand has achieved profitability through precise product positioning and market strategy in the functional probiotics segment [3] - The company minimizes reliance on influencer marketing, using it as a supplementary method rather than a core revenue source [3] - The shift towards activating owned brand traffic indicates a growing consumer recognition and repurchase intention for "Daily Doctor" [3]

Core Viewpoint - The Chinese government is promoting a "Weight Management Year" initiative, which is expected to significantly boost the health industry, potentially exceeding a trillion yuan in market size. This creates a favorable environment for companies like Junyao Health, which is focusing on expanding its leadership in the probiotic market and enhancing its product offerings [1][2]. Group 1: Company Performance - Junyao Health reported revenues of approximately 1.458 billion yuan for 2024 and 401 million yuan for the first quarter of 2025, with a notable 139.19% increase in probiotic food revenue in Q1 2025 [1][3][4]. - The company achieved a gross margin of 38.39% in 2024, an increase of 1.98% from the previous year, attributed to reduced raw material costs and optimized operational management [3][4]. Group 2: Market Trends - The health industry in China is projected to reach a market size of 13.4 trillion yuan by 2025 and further grow to 29.1 trillion yuan by 2030, driven by the "Healthy China 2030" strategy [2]. - The probiotic market in China has seen significant growth, with a compound annual growth rate of 14% from 2018 to 2022, increasing from 64.77 billion yuan to approximately 109.38 billion yuan [5]. Group 3: Product Development - Junyao Health is expanding its product line to include low-temperature active probiotic beverages, leveraging innovative fermentation technology and developing functional beverages that combine probiotics with other beneficial ingredients [2][4]. - The company has developed a diverse range of health functional beverages, including products targeting beauty, eye health, sleep, and nutrition, to meet various consumer health needs [2][4]. Group 4: Strategic Initiatives - Junyao Health is enhancing its research and development capabilities by integrating with leading companies in the probiotic sector, establishing a comprehensive "R&D-production-sales" integrated system to strengthen its market position [6][7]. - The company is expanding its e-commerce presence, with a significant increase in online sales, particularly in the first quarter of 2025, where e-commerce revenue surged by 1,173.33% [4][8]. Group 5: International Expansion - Junyao Health's international business achieved revenue of approximately 84.6 million yuan in 2024, a year-on-year increase of 24.54%, with Q1 2025 showing a remarkable growth of 77.43% [9]. - The company exports to over 80 countries and regions, positioning itself as a leading exporter of probiotics in China, benefiting from competitive pricing and stable supply chains [9]. Group 6: Future Outlook - With the release of production capacity, strengthened technological barriers, and expanded brand influence, Junyao Health is expected to continue leading the health industry and achieve long-term stable growth [10].